Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients

NCT03351361 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

217

Enrollment

OTHER

Sponsor class

Conditions

Advanced Non Small Cell Lung Cancer

Interventions

DRUG: Nivolumab + Ipilimumab
DRUG: Chemotherapy

Sponsor

Rennes University Hospital